A day after Elliott Management Corp. revealed a stake in athenahealth (ATHN) , Wall Street firms weighed in on the situation stating their confidence that the activist will be able to get its agenda through.

"Fundamentals remain a concern but the involvement of an activist limits [near term] downside and increases the chances of a sale," wrote Jefferies, Sean Dodge, adding that a sale is not the only outcome Athena could see, though likely.

"We believe the fund may push for a cost reduction program, given ATHN's revenue slow-down and high operating costs," added David Larsen of Leerink Partners LLC in a note Thursday, May 18.

The analyst noted Elliott's previous successes in the healthcare space including campaigns at The Advisory Board (ABCO) and AbbVie (ABBV) .

Jefferies upgraded its price target to $135 per share from $95, while Leerink upped its target to $140 per share from $110. Evercor ISI raised its price target to $147 per share following news of the filing.

Athenahealth shares soared on Thursday, May 18, Elliott's Paul Singer launched a campaign at the healthcare technology company urging it to consider "strategic opportunities."

In the filing, Elliott said it believed that athenahealth operates in a "highly strategic area at the intersection of technology and health care with a disruptive value proposition, a leading competitive position and a compelling product set, the value of which is not reflected in the Issuer's current market value."

Watertown, Mass.-based athenahealth is a provider of medical record, revenue cycle, patient engagement, care coordination and population health services.

"[Athena] is now a mature business in a slowing industry. The vast majority of physicians and hospitals in the U.S. have attested to Meaningful Use, and ATHN is facing much stiffer competition from [Cerner (CERN) ] and [Epic Systems Corp.]," wrote Leerink's Larsen, adding that recent comments from CEO Jonathan Bush about getting the company's margins to 20% are unrealistic.

In 2016 the company posted gross margin of 12.2% down from a high of 16.6% in 2011.

"M&A multiples have averaged 4.5x revenue over the last several years-not much higher than ATHN's current 4.3x valuation," according to Jefferies. "A sale is a low probability event but can't be ruled-out given the number of well-capitalized non-HC software companies looking to 'break into' healthcare."

Analysts polled by FactSet project the company to have about $1.2 billion in sales. 

Looking at the software landscape, IBM (IBM) and Inuit (INTU) have expressed a desire to break into healthcare while athena's competitor Cerner, which is growing at a much slower pace than athena could take a look. Reports have also speculated that Epic, Aetna (AET) and UnitedHealth (UNH) may also be interested. 

If you liked this article you might like

Athenahealth Stock Climbs Amid Strategic Review, Management Shakeup

Shares of Activist Target AthenaHealth Soar After Second Quarter Results

5 Things You Must Know Before the Market Opens Thursday

Mixed Signals Perplex Markets: Cramer's 'Mad Money' Recap (Friday 6/23/17)